BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He L, Yang H, Huang J. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma. BMC Cancer 2021;21:581. [PMID: 34016089 DOI: 10.1186/s12885-021-08328-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Tong Y, Zhang X, Zhou Y. Integrated Analysis of Multi-Omics Data to Establish a Hypoxia-Related Prognostic Model in Osteosarcoma. Evol Bioinform Online 2022;18:117693432211285. [DOI: 10.1177/11769343221128537] [Reference Citation Analysis]
2 Liu M, Xia S, Zhang X, Zhang B, Yan L, Yang M, Ren Y, Guo H, Zhao J. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC. Lung Cancer 2022;170:148-55. [DOI: 10.1016/j.lungcan.2022.06.016] [Reference Citation Analysis]
3 Guo H, Qian Y, Yu Y, Bi Y, Jiao J, Jiang H, Yu C, Wu H, Shi Y, Kong X. An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Front Oncol 2022;12:791867. [DOI: 10.3389/fonc.2022.791867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zeng Z, Li W, Zhang D, Zhang C, Jiang X, Guo R, Wang Z, Yang C, Yan H, Zhang Z, Wang Q, Huang R, Zhao Q, Li B, Hu X, Gao L. Development of a Chemoresistant Risk Scoring Model for Prechemotherapy Osteosarcoma Using Single-Cell Sequencing. Front Oncol 2022;12:893282. [PMID: 35664733 DOI: 10.3389/fonc.2022.893282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Djuričić GJ, Ahammer H, Rajković S, Kovač JD, Milošević Z, Sopta JP, Radulovic M. Directionally Sensitive Fractal Radiomics Compatible With Irregularly Shaped Magnetic Resonance Tumor Regions of Interest: Association With Osteosarcoma Chemoresistance. J Magn Reson Imaging 2022. [PMID: 35561019 DOI: 10.1002/jmri.28232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zheng D, Wei Z, Guo W. Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma. Front Genet 2022;13:849789. [PMID: 35518353 DOI: 10.3389/fgene.2022.849789] [Reference Citation Analysis]
7 Du Y, Han Y, Wang X, Wang H, Qu Y, Guo K, Ma W, Fu L. Identification of Immune-Related Breast Cancer Chemotherapy Resistance Genes via Bioinformatics Approaches. Front Oncol 2022;12:772723. [PMID: 35387129 DOI: 10.3389/fonc.2022.772723] [Reference Citation Analysis]
8 Jiang B, Kang X, Zhao G, Lu J, Wang Z. miR-138 Reduces the Dysfunction of T Follicular Helper Cells in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1. Comput Math Methods Med 2021;2021:2895893. [PMID: 34950224 DOI: 10.1155/2021/2895893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Casanova JM, Almeida JS, Reith JD, Sousa LM, Fonseca R, Freitas-Tavares P, Santos-Rosa M, Rodrigues-Santos P. Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival. Cancers (Basel) 2021;13:6075. [PMID: 34885185 DOI: 10.3390/cancers13236075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]